oncology
19 stories related to this topic, newest first.
manilatimes.netPerspective Therapeutics to Present Clinical Updates at 2026 ASCO Meeting
Perspective Therapeutics announced it will present data from three ongoing cancer treatment studies at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago from May 29 to June 2.
StatFDA Approves BeOne Medicines’ Beqalzi for Relapsed/Refractory Mantle Cell Lymphoma
BeOne Medicines received FDA approval for its BCL-2 inhibitor Beqalzi to treat relapsed or refractory mantle cell lymphoma. The drug is the first BCL-2 inhibitor specifically cleared for this indication in the U.S. Separately, CREATE Medicines raised $122 million to advance its i…
Fox NewsPatient Reports Symptom Improvement in Phase III Trial of Experimental Targeted Chemotherapy for Pancreatic Cancer
Hernando Salcedo, 83, experienced fewer side effects and regained energy after eight TAMP sessions delivered via RenovoRx's RenovoCath device at Miami Cancer Institute. Early TIGeR-PaC trial data showed trends toward better survival and 65% fewer adverse events. Enrollment is exp…
The IndependentUS Cancer Centers Report Surge in Requests for Experimental Pancreatic Cancer Drug
US cancer centers are seeing increased patient requests for daraxonrasib following positive clinical trial results that showed doubled survival rates for advanced pancreatic cancer. The FDA approved an expanded access program for the drug on 1 May, three weeks after the developer…
forbes.comStartup Develops System To Track Cancer Treatment Response In Real Time
A startup valued at $250 million has created technology that monitors how tumors respond to cancer treatments as they occur. The system aims to provide physicians with immediate data on treatment effectiveness rather than waiting for traditional scans. Forbes reported the develop…
benzinga.comMiNK Therapeutics Reports agenT-797 Produces Context-Dependent Immune Responses in Cancer and ARDS
MiNK Therapeutics presented clinical data at the ASGCT 2026 meeting showing its off-the-shelf iNKT cell therapy agenT-797 drove different immune responses in patients with solid tumors and those with acute respiratory distress syndrome. The same product batch from one donor activ…
BenzingaBristol Myers Squibb Agrees to Up to $15.2B Deal With Hengrui Pharma for 13 Early-Stage Programs
The deal covers 13 early-stage programs in oncology, hematology and immunology. Bristol Myers Squibb will pay up to $950 million in near-term payments while gaining rights to several drug candidates outside China.
app.buzzsumo.comDrug Daraxonrasib Extends Survival in Pancreatic Cancer Trial
A small clinical trial found that daraxonrasib, which blocks a family of mutant proteins, helped patients with a deadly form of pancreatic cancer live longer. The drug shrank or halted tumor growth in many participants. Nature reported the findings from the trial published in 202…
StatTrump Administration Announces Projected Savings From Drug Pricing Agreements
The Trump administration is touting massive projected savings from still-secret drug pricing deals even as outside experts question how independently verifiable the figures are. STAT reported on the claims alongside fresh accusations of political interference at the FDA, which wi…
forbes.comImmunai Expands Oncology Collaboration With AstraZeneca
The New York-headquartered, Israeli-founded AI biotech company Immunai has expanded its multi-year collaboration with AstraZeneca in oncology clinical development. Under the agreement, Immunai is eligible to receive up to $37.5 million over 2026 and 2027. The companies will conti…
Nbc NewsExperimental Pancreatic Cancer Drug Doubles Survival in Advanced Cases
An experimental drug called daraxonrasib has shown it can double survival time for patients with advanced pancreatic cancer when combined with chemotherapy. The Food and Drug Administration has fast-tracked the drug for approval and allowed expanded access outside clinical trials…
Substrate placeholder — needs reviewAstraZeneca Reports Higher-Than-Expected First-Quarter Revenue and Profit
AstraZeneca announced an 8 percent increase in first-quarter revenue to $15.29 billion, exceeding analyst forecasts. The growth was driven by oncology and rare disease segments. The company reaffirmed its full-year outlook for revenue and earnings growth.
insidermonkey.comEli Lilly Agrees to Acquire Ajax Therapeutics for Up to $2.3 Billion
Eli Lilly announced it will acquire privately held Ajax Therapeutics for up to $2.3 billion in cash to strengthen its blood cancer treatment portfolio. The deal focuses on Ajax's lead experimental drug for myelofibrosis, a rare chronic blood cancer. It includes an upfront payment…
Substrate placeholder — needs reviewSutro Biopharma Presents Preclinical Data on ADC Programs at AACR 2026
Sutro Biopharma announced preclinical data for its antibody drug conjugate programs at the American Association for Cancer Research Annual Meeting 2026. The data covered STRO-004 and other next-generation ADCs, showing antitumor activity in solid tumor models. Initial Phase 1 stu…
Substrate placeholder — needs reviewGSK Plans Five Simultaneous Late-Stage Trials for Potential Blockbuster Cancer Drug
GSK Plc announced plans for five concurrent phase 3 trials of a targeted cancer therapy following promising early data. The initiative aims to advance the drug toward potential blockbuster status. The new CEO is leading efforts to revitalize the company's approach to innovation.
Substrate placeholder — needs reviewRevolution Medicines Advances Testing of Pancreatic Cancer Treatment Pill
Revolution Medicines is conducting clinical trials for a pill targeting pancreatic cancer. The treatment aims to address a disease with limited effective options. CNBC reported on the company's latest developments in this area.
Substrate placeholder — needs reviewChallenges in Targeting Cancer Tumors with Immunotherapies and Viral Proteins
Immunotherapies and viral proteins that induce cell death serve as tools in cancer treatment. These methods face difficulties in selectively targeting tumors without affecting healthy cells. Researchers continue to explore ways to improve precision in such therapies.
Substrate placeholder — needs reviewTumor Mutations Often Unidentified, Limiting Use of Advanced Targeted Therapies
Many advanced targeted therapies remain unused because mutations in tumors are not identified through testing. According to STAT News, this gap affects patient treatment options in oncology. The issue highlights challenges in precision medicine implementation.
Substrate placeholder — needs reviewOncologist Reflects on Admitting Uncertainty in Patient Care Over 25 Years
An oncologist with 25 years of experience discusses the challenges of addressing patient questions amid medical uncertainties. The article highlights advancements in medicine, such as HIV treatment and stroke interventions, while noting the persistence of unpredictable outcomes i…